Please login to the form below
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Drug usage/utilisation review (DUR)
Drug Utilization Reviews (DUR), also referred to as Drug Utilization Evaluations (DUE) is a pharmacoeconomic programme that reviews, analyses and interprets rates, costs and appropriateness of drug usage to assess inappropriate use, prevent adverse drug interactions and optimise appropriate use.
DURs involve a comprehensive review of patients' prescription and medication information before, during, and after dispense to ensure relevent medication decision making and positive patient outcomes.
See also:
Economic evaluation
Adverse reaction
Adherence
Concordance
Related terms
Geo-demographics, Mathematical analysis of perception and preference (MAPP), Methodology, Performance prism, Trial endpoint, Phase I trials, Fair balance, Ansoff Matrix, Disease mongering, Cost-minimisation analysis (CMA), Randomised trial, Prescription only medicine (POM), Brainstorm, Over the counter (OTC), Cost-effectiveness (in media/advertising),
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Editorial Team Leader, Medical Communications, Oxford
-
Competitive Salary
-
Head of Copy
-
£ competitive
-
Account Manager
-
Competitive salary with bonus and benefits
- Graduate Business Analyst, Healthcare Communications – Pharma/ S...
-
Highly competitive salary
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- GSK appoint Tony Wood as chief scientific officer
- Almirall and IRB Barcelona announce new research collaboration
- PM announces plans to lift England’s COVID-19 restrictions
- Let's explore new frontiers
- FDA grants priority review for Roche’s Evrysdi for spinal muscular atrophy in babies
- Ipsen’s Sohonos approved by Health Canada
- Personalised medicine: driving a need for greater diversity in clinical trials
- Live Webinar: Protecting Ownership of Technological & Pharmaceutical Innovation
- Lucid Group Welcomes a New Cohort of Graduates into its Futures Academy
- Why pharma must get smart in its approach to customer engagement
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
- Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
- Amgen’s Lumykras receives conditional marketing authorisation from EC
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
PMHub
foxandcat.online
some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...
